<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02979587</url>
  </required_header>
  <id_info>
    <org_study_id>MDT16004CON001</org_study_id>
    <nct_id>NCT02979587</nct_id>
  </id_info>
  <brief_title>The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study</brief_title>
  <official_title>The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Heart Valves</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further evaluate the safety and effectiveness of the Harmony™
      TPV system.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from procedure- or device-related mortality at 30 days.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with acceptable hemodynamic function composite at 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as:
Mean RVOT gradient as measured by continuous‐wave Doppler ≤40 mmHg ‐AND‐
Pulmonary regurgitant fraction as measured by magnetic resonance imaging &lt;20%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success at exit from catheterization lab/operating room (OR)</measure>
    <time_frame>At exit from catheterization lab/operating room (OR)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success out to 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success at 30 days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from TPV Dysfunction out to 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety</measure>
    <time_frame>5 years</time_frame>
    <description>All procedure-related serious adverse events. All device-related serious adverse events. Death (all-cause, procedural, and device-related).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of quality of life scores out to 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>As assessed via the SF-36 QOL form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of right ventricle remodeling following TPV implant</measure>
    <time_frame>5 years</time_frame>
    <description>As assessed via cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Tetrology of Fallot</condition>
  <condition>RVOT Anomaly</condition>
  <condition>Pulmonary Regurgitation</condition>
  <arm_group>
    <arm_group_label>Harmony TPV System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention Device: Harmony Transcatheter Pulmonary Valve and Delivery System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Harmony TPV System</intervention_name>
    <description>The Harmony™ TPV is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame. The Harmony Delivery System is a 25 Fr coil loading catheter delivery system.</description>
    <arm_group_label>Harmony TPV System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has severe pulmonary regurgitation as assessed via echocardiography or CMR
             determined PR fraction &gt;/= 30%

          -  Subject has clinical indication for surgical placement of an RV-PA conduit or
             bioprosthetic pulmonary valve

          -  Subject is willing to consent to participate

        Exclusion Criteria:

          -  Patients with right ventricular outflow tract obstruction (RVOTO) lesions surgically
             treated with an RV-to-PA conduit implant

          -  RVOT anatomy or morphology that is unfavorable for device anchoring

          -  Positive pregnancy test

          -  Life expectancy of less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Cheatham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie J Salisbury</last_name>
    <phone>+16129797251</phone>
    <email>stephanie.salisbury@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harmony Clinical Study Central Email</last_name>
    <email>rs.harmonytpvclinicalstudy@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ronald Regan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Levi, MD</last_name>
      <phone>310-267-7667</phone>
      <email>dlevi@ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Levi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doff McElhinney, MD</last_name>
      <phone>650-736-9364</phone>
      <email>doff@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Doff McElhinney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Asnes, MD</last_name>
      <phone>203-785-2022</phone>
      <email>jeremy.asnes@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy Asnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Cabalka, MD</last_name>
      <phone>507-255-5123</phone>
      <email>Cabalka.Allison@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Allison Cabalka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P Cheatham, MD, MSCAI</last_name>
      <phone>614-722-6124</phone>
      <email>John.Cheatham@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Joanne L Chisolm, MSN, RN</last_name>
      <phone>614-355-5736</phone>
      <email>Joanne.Chisolm@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>John P Cheatham, MD, MSCAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Gillespie, MD</last_name>
      <phone>215-590-1790</phone>
      <email>GILLESPIE@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Gillespie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri Justino, MD</last_name>
      <phone>832-824-1000</phone>
      <email>hxjustin@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Henri Justino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gray, MD</last_name>
      <phone>801-662-1000</phone>
      <email>Robert.Gray@utah.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Gray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Jones, MD</last_name>
      <phone>206-987-2000</phone>
      <email>thomas.jones@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sickkids Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lee Benson, MD</last_name>
      <phone>416-813-6141</phone>
      <email>lee.benson@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Lee Benson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Horlick, MD</last_name>
      <phone>416 340 3835</phone>
      <email>Eric.Horlick@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Eric Horlick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

